Opioid Use Disorder Phase I/II Clinical Trial

In the face of an unprecedented opioid crisis, finding effective treatments for Opioid Use Disorder (OUD) is an urgent public health priority. Current options, while beneficial, have shown limitations in treatment retention. This trial, led by Edythe D. London, Ph.D. at UCLA, aims to explore a potential adjunctive therapy for OUD using cannabidiol (CBD) in a measured and rigorous manner.

Preclinical and initial clinical studies have provided encouraging signals regarding CBD’s potential to address OUD. Animal models indicate that CBD may play a role in preventing relapse, offering hope for patients in recovery. Promisingly, a pilot study demonstrated that CBD could reduce cue-induced opioid cravings and anxiety. However, it is crucial to conduct a rigorous clinical trial to determine the optimal dosage and establish the full potential of CBD as an adjunctive therapy for OUD.

This clinical trial involving 60 subjects, focuses primarily on evaluating the safety and tolerability of Nantheia™ ATL5, Ananda’s investigational CBD drug utilizing it proprietary Liquid Structure ™ delivery technology. Additionally, secondary endpoints encompass reduction in cue-induced cravings, drug-drug interaction evaluation, and the effects of CBD on endocannabinoid metabolism. The ultimate goal is to provide a safe and effective medication to help prevent opioid-related deaths.

For more details, refer to the clinicaltrials.gov link (https://clinicaltrials.gov/study/NCT03787628) and press releases issued over the course of the study:

ANANDA Scientific and David Geffen School of Medicine UCLA Announce Clinical Trial Utilizing Liquid Structure™ Cannabidiol (CBD) for the Treatment of Opioid Use Disorder (OUD)

ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)

ANANDA Scientific Announces First Patient Enrolled in the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)